- Home
- TSVT vs ADVM Comparison
TSVT vs ADVM Comparison
Compare TSVT & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- ADVM
- Stock Information
- Founded
- TSVT 2021
- ADVM 2006
- Country
- TSVT United States
- ADVM United States
- Employees
- TSVT N/A
- ADVM N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TSVT Health Care
- ADVM Health Care
- Exchange
- TSVT Nasdaq
- ADVM Nasdaq
- Market Cap
- TSVT 160.4M
- ADVM 161.4M
- IPO Year
- TSVT N/A
- ADVM 2014
- Fundamental
- Price
- TSVT $3.16
- ADVM $5.75
- Analyst Decision
- TSVT Buy
- ADVM Strong Buy
- Analyst Count
- TSVT 6
- ADVM 6
- Target Price
- TSVT $10.40
- ADVM $27.83
- AVG Volume (30 Days)
- TSVT 339.4K
- ADVM 223.9K
- Earning Date
- TSVT 11-12-2024
- ADVM 11-04-2024
- Dividend Yield
- TSVT N/A
- ADVM N/A
- EPS Growth
- TSVT N/A
- ADVM N/A
- EPS
- TSVT N/A
- ADVM N/A
- Revenue
- TSVT $45,620,000.00
- ADVM $1,000,000.00
- Revenue This Year
- TSVT N/A
- ADVM N/A
- Revenue Next Year
- TSVT $31.98
- ADVM $1,294.35
- P/E Ratio
- TSVT N/A
- ADVM N/A
- Revenue Growth
- TSVT N/A
- ADVM N/A
- 52 Week Low
- TSVT $1.68
- ADVM $5.82
- 52 Week High
- TSVT $6.40
- ADVM $29.70
- Technical
- Relative Strength Index (RSI)
- TSVT 24.53
- ADVM 24.35
- Support Level
- TSVT $4.81
- ADVM $6.81
- Resistance Level
- TSVT $5.12
- ADVM $7.73
- Average True Range (ATR)
- TSVT 0.31
- ADVM 0.46
- MACD
- TSVT -0.16
- ADVM -0.23
- Stochastic Oscillator
- TSVT 6.67
- ADVM 2.02
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.